THE PROMID STUDY: OCTREOTIDE LAR IN
MIDGUT NETS – WHAT DID WE LEARN?
Lessons
Limitations
Octreotide LAR shows
antitumor effect in:
•
Midgut tumors
•
Low hepatic tumor
burden (<10%)
•
Grade 1 tumors
The efficacy of
Octreotide LAR is
uncertain in:
•
Non-midgut tumors
•
Higher liver tumor
burden (<10%)
•
Grade 2 tumors
•
Stable disease
•
Progressive disease
